Walking the tightrope: a balanced discussion of the benefits and harms of extended duration anticoagulation for venous thrombo-embolism
- 19 January 2023
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (14) , 1245-1247
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous ThromboembolismAnnals of Internal Medicine, 2021
- Deciding on Treatment Duration for Unprovoked Venous Thromboembolism: What is Important to Patients?Thrombosis and Haemostasis, 2021
- The 2019 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary EmbolismEuropean Heart Journal, 2019
- Racial, Ethnic, and Socioeconomic Inequities in the Prescription of Direct Oral Anticoagulants in Patients With Venous Thromboembolism in the United StatesCirculation: Cardiovascular Quality and Outcomes, 2019
- Let’s Stop Dichotomizing Venous Thromboembolism as Provoked or UnprovokedCirculation, 2018
- Rivaroxaban or Aspirin for Extended Treatment of Venous ThromboembolismNew England Journal of Medicine, 2017
- Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTHJournal of Thrombosis and Haemostasis, 2016
- Apixaban for Extended Treatment of Venous ThromboembolismNew England Journal of Medicine, 2013
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous ThromboembolismNew England Journal of Medicine, 2013
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010